AGS 62P1

Drug Profile

AGS 62P1

Alternative Names: AGS62P1

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Ambrx
  • Developer Agensys
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 10 Nov 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA and Canada (IV) (NCT02864290)
  • 09 Aug 2016 Agensys and Astellas Pharma plan a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA and Canada (IV) (NCT02864290)
  • 16 Apr 2016 Preclinical trials in Leukaemia in USA (Parenteral) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top